Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Enlivex Therapeutics Ltd.

    NASDAQ: ENLV · Real-Time Price · USD
    1.02
    -0.01 (-0.97%)
    At close: Jun 17, 2025, 3:59 PM
    0.96
    -5.87%
    After-hours: Jun 17, 2025, 05:14 PM EDT

    Enlivex Therapeutics Statistics

    Share Statistics

    Enlivex Therapeutics has 23.85M shares outstanding. The number of shares has increased by 5.36% in one year.

    Shares Outstanding

    n/a
    		 23.85M

    Shares Change (YoY)

    n/a
    		 5.36%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 16.03%

    Shares Floating

    n/a
    		 22.66M

    Failed to Deliver (FTD) Shares

    n/a
    		 14

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 98.58K, so 0.46% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 98.58K

    Short % of Shares Out

    n/a
    		 0.46%

    Short % of Float

    n/a
    		 0.49%

    Short Ratio (days to cover)

    n/a
    		 2.03

    Valuation Ratios

    The PE ratio is -1.6 and the forward PE ratio is -1.51. Enlivex Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -1.6

    Forward PE

    n/a
    		 -1.51

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.02

    P/FCF Ratio

    n/a
    		 -1.83

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Enlivex Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 6.84

    Quick Ratio

    n/a
    		 6.84

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.04

    Debt / FCF

    n/a
    		 -0.04

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-211,464.79

    Employee Count

    n/a
    		 71

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -26.62% in the last 52 weeks. The beta is 0.74, so Enlivex Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.74

    52-Week Price Change

    n/a
    		 -26.62%

    50-Day Moving Average

    n/a
    		 0.96

    200-Day Moving Average

    n/a
    		 1.17

    Relative Strength Index (RSI)

    n/a
    		 59.1

    Average Volume (20 Days)

    n/a
    		 62,685

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 -545K

    Operating Income

    n/a
    		 -15.54M

    Net Income

    n/a
    		 -15.01M

    EBITDA

    n/a
    		 -14.47M

    EBIT

    n/a
    		 -15.01M

    Earnings Per Share (EPS)

    n/a
    		 -0.73
    Full Income Statement

    Balance Sheet

    The company has 3.3M in cash and 534K in debt, giving a net cash position of 2.77M.

    Cash & Cash Equivalents

    n/a
    		 3.3M

    Total Debt

    n/a
    		 534K

    Net Cash

    n/a
    		 2.77M

    Retained Earnings

    n/a
    		 -127.11M

    Total Assets

    n/a
    		 27.69M

    Working Capital

    n/a
    		 22.19M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -13.01M and capital expenditures -103K, giving a free cash flow of -13.11M.

    Operating Cash Flow

    n/a
    		 -13.01M

    Capital Expenditures

    n/a
    		 -103K

    Free Cash Flow

    n/a
    		 -13.11M

    FCF Per Share

    n/a
    		 -0.64
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ENLV does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ENLV is $13, which is 1174.5% higher than the current price. The consensus rating is "Strong Buy".

    Price Target

    n/a
    		 $13

    Price Target Difference

    n/a
    		 1174.5%

    Analyst Consensus

    n/a
    		 Strong Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 6, 2019. It was a backward split with a ratio of 1:8.

    Last Split Date

    n/a
    		 Mar 6, 2019

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:8

    Scores

    Altman Z-Score

    n/a
    		 -3.96

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist